AngioDynamics Appoints Navilyst Executive as CTO

Following the announcement of its acquisition of Navilyst Medical Inc., Albany, N.Y.-based AngioDynamics Inc. has appointed George W. Bourne as senior vice president and chief technology officer. The acquisition is valued at $353.7 million.

Bourne served as senior vice president of research and development (R&D) and clinical affairs for Navilyst Medical, a medical device manufacturer focused in the vascular access sector, from its formation in early 2008 until November 2011. His tenure was defined by focused portfolio development and the commercialization of new products. Most recently, he served as vice president of R&D at Hologic. Previously, he spent ten years at Boston Scientific as vice president of R&D of the urology, medtech and oncology business units and then as group vice president of R&D for the endosurgery business group. He also served in leadership positions at Baxter Healthcare, Allegiance Healthcare and C.R. Bard. Bourne earned his Bachelor of Science in Biological Science and Master of Science in Plastics Engineering from the University of Lowell in Lowell, Mass., and his MBA from Rivier College in Nashua, N.H.

“George is a world-class engineer whose commitment to operational excellence has led him to establish and manage high-performance medical device R&D organizations,” said Joseph M. DeVivo, CEO of AngioDynamics. “His extensive knowledge of Navilyst Medical’s technology, pipeline and organization, combined with 25 years of experience in developing products in global medical device companies, make George the ideal fit for this important executive role.”

Bourne said: “The combination of AngioDynamics and Navilyst will create a more comprehensive and competitive portfolio of products differentiated by advanced technologies. I look forward to working with Joseph DeVivo and his team to expand our product offering and drive growth.”

AngioDynamics’ acquisition of Navilyst Medical is expected to expand the company’s reach, doubling its share of the vascular access market, while “building critical mass” in the peripheral vascular market, according to company execs. Under the terms of the agreement, AngioDynamics will acquire Navilyst Medical from Avista Capital Partners, a private equity firm, for $373.7 million in cash and stock.

AngioDynamics provides minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology.